one hallmark advanc prostat cancer faulti pten tumor suppressor gene . screen compound effect cell lack pten scientist discov natur insecticid call deguelin kill cell disrupt energi suppli . research reveal natur insecticid destroy advanc prostat cancer cell . deguelin belong class drug known mitochondri inhibitor . drug block action mitochondria . mitochondria tini compart insid cell convert glucos cell molecul adenosin triphosph atp serv unit energi fuel variou work cell . scientist cold spring harbor laboratori new york found treat cell lack pten type mitochondri inhibitor caus cell use glucos environ make atp transport mitochondria preserv . though cell without pten explain studi leader lloyd trotman professor cold spring harbor laboratori driven `` consum vast quantiti glucos '' help mitochondria surviv . point run fuel die . research describ work includ use genet mous model metastat prostat cancer develop prof. trotman group paper publish journal cell report . suggest find show right dose certain mitochondri inhibitor deguelin anoth identifi call rotenon may abl kill prostat cancer cell without harm healthi cell . howev also note time condit right â€“ exampl drug would work glucos level high . `` hope '' prof. trotman explain `` care time administr drug gener much better window select kill . '' prostat cancer tumor suppressor skin cancer prostat cancer common cancer men unit state 2017 estim 161360 peopl discov diseas . vast major case prostat cancer diagnos diseas start spread . cancer local state much easier treat 5year surviv rate close 100 percent . howev cancer becom metastat spread set new tumor part bodi much harder treat . men diagnos metastat advanc prostat cancer averag 5year surviv rate 29 percent . studi paper author note `` hallmark advanc prostat cancer '' two tumor suppressor gene pten p53 work properli mutat . tumor suppressor gene work properli `` slow cell divis '' repair broken dna trigger program cell death . faulti tumor suppressor gene hand fail carri function give rise faulti cell grow uncontrol caus cancer . deguelin stop cancer progress prof. trotman colleagu suggest 3 million men u.s. prostat cancer `` roughli 100000 carri cancer comut pten p53 . '' `` prompt '' look drug might work specif prostat cancer carri mutat pten p53 . howev `` sever studi '' shown loss p53 give rise prostat cancer decid focu pten . shapeshift cancer cell promot metastasi learn loss certain protein make prostat cancer cell abl chang shape migrat invad tissu . read research began studi run seri experi use cell without pten . found deguelin capac kill type cell dose requir kill cell pten normal cell model 500 time higher dose requir kill cell without pten cancer cell model . also discov drug much stronger effect cell without pten mitochondria consum atp `` instead produc . '' `` that exact opposit '' prof. trotman say `` mitochondria suppos . mitochondria suppos gener atp rest cell . '' final test deguelin mous model `` lethal '' metastat prostat cancer research found stop cancer progress . drug requir low glucos level research suggest `` vulner '' find identifi ptendefici cell may pave way `` highli select target incur '' prostat cancer use mitochondri inhibitor . metformin wide prescrib diabet drug also mitochondri inhibitor alreadi test clinic trial anticanc treatment . author note case prostat cancer treatment metformin seem reduc diseas death incid . `` suggest '' add `` metformin may preferenti target aggress prostat cancer '' current trial tri find . propos new find `` contribut effort . '' howev note studi also suggest one condit necessari mitochondri inhibitor `` maxim select kill '' power `` deplet tumor cell glucos suppli . '' would indic need treatment scenario opposit diabet metformin taken meal blood glucos level high . author conclud '' result instead suggest greater select might achiev drug given blood glucos level low . ''